Finding Consistent With Earlier Study of Breast Cancer in Mice
COLUMBIA, Md., Dec. 10 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (NASDAQ: MATK) today announced study results demonstrating that its docosahexaenoic acid (DHA) significantly inhibited the growth of human colon cancer cells in mice. The study, published today in Cancer Letters, found that while both Martek's DHA oil and fish oil, containing both DHA and eicosapentaenoic acid (EPA), inhibited colon cancer cell growth, Martek's DHA had a greater effect.
Researchers at the University of Nevada, Reno, measured the influence of Martek's DHA oil, fish oil (omega-3), and corn oil (omega-6) supplementation on the growth of human colon adeno carcinoma in mice. The animals received one of four specialized diets, low fat with corn oil (omega-6), high fat with corn oil (omega-6), high fat with fish oil (omega-3 EPA and DHA), and high fat with Martek's DHA (omega-3 DHA). At the study's completion, the mice receiving a diet supplemented with Martek's plant-derived DHA had tumors that were smaller than those of mice receiving diets supplemented with omega-3 from fish oil as well as those fed both the high and low fat corn oil (omega-6) diets. These results show that omega-3 fatty acids possess significant tumor suppressing properties and that the primary tumor suppressing fatty acid is DHA.
The potential role of Martek's DHA in cancer treatment has been the subject of previous preclinical investigations. Researchers from the American Health Foundation (since renamed The Institute for Cancer Prevention) announced clinical data demonstrating that Martek's DHA suppressed human breast cancer metastasis in mice at the 21st Annual Breast Cancer Symposium in December 1998. Those findings led Martek and the Yale School of Medicine to initiate a collaborative agreement to conduct a pilot study on the use of DHA as a possible breast cancer prevention agent in July 2000.
"The fact that a second independent animal study shows that Martek's DHA suppresses cancer activity is very encouraging," stated Henry "Pete" Linsert, Jr., Martek Chairman and CEO.
Martek Biosciences Corporation develops, manufactures and sells products from microalgae. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) new, powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection.
This press release contains forward-looking statements regarding Martek's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.